2013: The "seville" document on Consensus on the Alternatives to Allogenic Blood Transfusion;2013: Documento «sevilla» de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica

Farmacia Hospitalaria

Volumn 37, Issue 3, 2013, Pages 209-235

  Leal Noval, S R ^a   Munoz M ^a   Asuero, M ^a   Contreras, E ^a   Garcia Erce J A ^a   Llau, J V ^a   Moral, V ^a   Paramo J A ^a   Quintana, M ^a  

^a NONE

Author keywords

Alternatives to allogeneic blood transfusion; Anemia; Fibrinogen; Haemoglobin

Indexed keywords

ALLOGENIC BLOOD TRANSFUSION; ANEMIA; BLOOD TRANSFUSION; CONSENSUS DEVELOPMENT; ERYTHROCYTE CONCENTRATE; HEALTH CARE POLICY; HUMAN; MEDICAL LITERATURE; REVIEW;

BLOOD LOSS, SURGICAL; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; BLOODLESS MEDICAL AND SURGICAL PROCEDURES; ERYTHROCYTE TRANSFUSION; HUMANS; OPERATIVE BLOOD SALVAGE; THROMBELASTOGRAPHY;

EID: 84882298820     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.7399/FH.2013.37.3.133     Document Type: Review

References (223)

1. Leal-Noval Sr, Alberca I, Asuero MS, Bóveda JL, Carpio N, Contreras E, et al. Documento Sevilla de consenso sobre alternativas a la transfusion de sangre alogénica. Med Clín (Barc.). 2006;127 (supl 1):3-20. (Pubitemid 47434979)
2. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008; 336:1049-51.
3. Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
4. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129:174-81. (Pubitemid 43265259)
5. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. Transfusion Requirements in Critical Care Investigators, Canadian Critical CareTrials Group. A multi-center, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-17. (Pubitemid 29084771)
6. Lacroix J, Hébert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356:1609-19. (Pubitemid 46631670)
7. Grover M, Talwalkar S, Casbard A, Boralessa H, Contreras M, Boralessa H, et al. Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang. 2006;90:105-12 (Pubitemid 43381498)
8. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, et al. Red blood cell transfusion: A clinical practical guideline from the AABB. Ann Intern Med. 2012;157:49-58.
9. Gerbert DR. Transfusion of packed red blood cells in patients with ischemic heart disease. Crit Care Med. 2008;36:1068-74.
10. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. New Engl J Med. 2001;345:1230-6. (Pubitemid 34951486)
11. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, Gibson CM, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111: 2042-9. (Pubitemid 40577898)
12. Möhnle P, Snyder-Ramos SA, Miao Y, Kulier A, Böttiger BW, Levin J, et al. Multicenter Study of Perioperative Ischemia [McSPI] Research Group. Intensive Care Med. 2011;37:97-109.
13. Haijar LA, Vincent JL, Galas FRBG, Nakamura RE, Silva CMP, Santos MH, et al. Transfusion requirements after cardiac surgery. The TRACS randomized controlled trial. JAMA. 2010;304:1559-67.
14. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365:2453-62.
15. Leal-Noval SR, Jiménez-Sánchez M. La transfusión de hematíes incrementa la oxigenación tisular y mejora el resultado clinic (con) Med Intensiva. 2010;34:471-5.
16. Kramer AH, Zygun DA. Anemia and red blood cell transfusion in neurocritical care. Crit Care. 2009;13:R89.
17. Leal-Noval SR, Muñoz-Gómez M, Murillo-Cabezas F. Optimal hemoglobin concentration in patients with subarachnoid hemorrhage, acute ischemic stroke and traumatic brain injury. Curr Opin Crit Care. 2008;14:156-62. (Pubitemid 351498780)
18. Carless P, Moxey A, O'Connell D, Henry D. Autologous transfusion techniques: a systematic review of their efficacy. Transf Med. 2004;14:123-44. (Pubitemid 38623075)
19. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81:2-10. (Pubitemid 29068441)
20. Feagan BG, Wong CJ, Johnston WC, Arellano R, Colterjohn N, Karkouti K, Turner K. Transfusion practices for elective orthopedic surgery. CMAJ. 2002;166:310-4. (Pubitemid 34132948)
21. Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43:459-69. (Pubitemid 36428328)
22. Freedman J, Luke K, Escobar M, Vernich L, Chiavetta JA. Experience of a network of transfusion coordinators for blood conservation (Ontario Transfusion Coordinators [ONTraC]). Transfusion. 2008;48:237-50.
23. Keating EM, Callaghan JJ, Ranawat AS, Bhirangi K, Ranawat CS. A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. J Arthroplasty. 2007;22:325-33. (Pubitemid 46505220)
24. Woolson ST, Wall WW. Autologous blood transfusion after total knee arthroplasty: a randomized, prospective study comparing predonated and postoperative salvage blood. J Arthroplasty. 2003;18:243-9. (Pubitemid 36542578)
25. Ridgeway S, Tai C, Alton P, Barnardo P, Harrison DJ. Pre-donated autologous blood transfusion in scoliosis surgery. J Bone Joint Surg Br. 2003;85-B:1032-6. (Pubitemid 37160690)
26. Bess RS, Lenke LG, Bridwell KH, Steger-May K, Hensley M. Wasting of preoperatively donated autologous blood in the surgical treatment of adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2006 15;31:2375-80. (Pubitemid 44423538)
27. Franchini M, Gandini G, Regis D, De Gironcoli M, Cantini M, Aprili G. Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion. 2004;44:1122-4.
28. García-Erce JA, Solano VM, Sáez M, Muñoz M. Recombinant human erythropoietin facilitates autologous blood donation in children undergoing corrective spinal surgery. Transfusion. 2005;45:820-1.
29. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang. 1998;75:128-33. (Pubitemid 28490883)
30. Dietrich W, Thuermel K, Heyde S, Busley R, Berger K. Autologous blood donation in cardiac surgery: reduction of allogeneic blood transfusion and cost-effectiveness. J Cardiothorac Vasc Anesth. 2005;19:589-96. (Pubitemid 41395017)
31. Muñoz M, Campos A, García-Erce JA. Intravenous iron in colorectal cancer surgery. Semin Hematol. 2006;43 (suppl 6):S36-S38. (Pubitemid 44486325)
32. Waters JH, Lee JS, Klein E, O'Hara J, Zippe C, Potter PS. Preoperative autologous donation versus cell salvage in the avoidance of allogeneic transfusion in patients undergoing radical retropubic prostatectomy. Anesth Analg. 2004;98:537-42. (Pubitemid 38129411)
33. Ishizawa T, Hasegawa K, Tsuno NH, Tanaka M, Mise Y, Aoki T, et al. Predeposit autologous plasma donation in liver resection for hepa-tocellular carcinoma: toward allogenic blood-free operations. J Am Coll Surg. 2009;209:206-14.
34. Comité de Acreditación en Transfusión (CAT). Estándares de Acreditación. 3a Edición. 2006.
35. Real Decreto 1088/2005 de 16 de septiembre, por el que se establecen los requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión. BOE 225, 2.
36. Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion. 2004;44:632-44. (Pubitemid 38608238)
37. Mehr-Aein A, Davoodi S, Madani-Civi M. Effects of tranexamic acid and autotransfusion in coronary artery bypass. Asian Cardiovasc Thorac Ann. 2007;15:49-53. (Pubitemid 46389959)
38. Sociedad Española de Transfusion Sanguínea y Terapia Celular. Guía sobre la transfusión de componentes sanguíneos y derivados plasmáticos. 4a Ed. SETS, Barcelona, 2010.
39. Karkouti K, Beatties WS, Wijeysundera DN, Rao V, Chan C, Dattilo KM, et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. Thorac Cardiovasc Surg. 2005;129:391-400. (Pubitemid 40169564)
40. Wypij D, Jonas RA, Bellinger DC, Del Nido PJ, Mayer JE Jr, Bacha EA, et al. The effect of hematocrit during hypothermic cardio -pulmonary bypass in infant heart surgery: results from the combined Boston hematocrit trials. J Thorac Cardiovasc Surg. 2008;135:355-60. (Pubitemid 351173108)
41. Bennett J, Haynes S, Torella F, Grainger H, McCollum C. Acute normovolemic hemodilution in moderate blood loss surgery: a randomized controlled trial. Transfusion. 2006;46:1097-103. (Pubitemid 44139482)
42. Thomas D, Wareham K, Cohen D, Hutchings H. Autologous blood transfusion in total knee replacement surgery. Br J Anaesth. 2001;86:669-73. (Pubitemid 32409409)
43. Muñoz M, Ariza D, Florez A, Campos A. Reinfusion drains reduce postoperative transfusion requirements after primary total knee replacement surgery. Transfus Med. 2008;18:269-71.
44. Mirza SB, Campion J, Dixon JH, Panesar SS. Efficacy and economics of postoperative blood salvage in patients undergoing elective total hip replacement. Ann R Coll Surg Engl. 2007;89-B:777-84. (Pubitemid 350193689)
45. Trujillo MM, Carrero A, Muñoz M. The utility of the perioperative autologous transfusion system OrthoPAT in total hip replacement surgery: a prospective study. Arch Orthop Trauma Surg 2008;128:1031-8.
46. Phillips SJ, Chavan R, Porter ML, Kay PR, Hodgkinson JP, Purbach B, et al. Does salvage and tranexamic acid reduce the need for blood transfusion in revision hip surgery? J Bone Joint Surg Br. 2006;88:1141-2. (Pubitemid 44404584)
47. Sebastián C, Romero R, Olalla E, García-Vallejo JJ, Muñoz M. Postoperative blood salvage and reinfusion in spinal surgery: blood quality, effectiveness and impact on patient blood parameters. Eur Spine J. 2000;9:458-65. (Pubitemid 32005648)
48. Gause PR, Siska PA, Westrick ER, Zavatsky J, Irrgang JJ, Kang JD. Efficacy of intraoperative cell saver in decreasing postoperative blood transfusions in instrumented posterior lumbar fusion patients. Spine (Phila Pa 1976). 2008;33(5):571-5. (Pubitemid 351644464)
49. Mirza AH, Aldlyami E, Bhimarasetty C, Thompson AG, Spilsbury J, Marks DS. The role of peri-operative cell salvage in instrumented anterior correction of thoracolumbar scoliosis: a case-controlled study. Acta Orthop Belg. 2009;75:87-93.
50. Rubens FD, Boodhwani M, Mesana T, Wozny D, Wells G, Nathan HJ. Cardiotomy Investigators. The cardiotomy trial: a randomized, double-blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocognitive function. Circulation. 2007;116 (11 Suppl):I89-97. (Pubitemid 47480775)
51. Murphy GJ, Allen SM, Unsworth-White J, Lewis CT, Dalrymple-Hay MJ. Safety and efficacy of perioperative cell salvage and autotransfusion after coronary artery bypass grafting: a randomized trial. Ann Thorac Surg. 2004;77:1553-9. (Pubitemid 38529981)
52. Murphy GJ, Rogers CS, Lansdowne WB, Channon I, Alwair H, Cohen A, et al. Safety, efficacy, and cost of intraoperative cell salvage and autotransfusion after off-pump coronary artery bypass surgery: a randomized trial. J Thorac Cardiovasc Surg. 2005;130:20-8. (Pubitemid 40941664)
53. Tawfick WA, O'Connor M, Hynes N, Sultan S. Implementation of the Continuous AutoTransfusion System (C.A.T.S) in open abdominal aortic aneurysm repair: an observational comparative cohort study. Vasc Endovascular Surg. 2008;42:32-9. (Pubitemid 351171530)
54. Serracino-Inglott F, Awad S, Barclay A, Nasim A. The use of a cell saver during repair of ruptured abdominal aortic aneurysms increases early survival [Letter]. Ann R Coll Surg Engl. 2005;87:475. (Pubitemid 41645543)
55. Donayre C, Adimora U, Song T, Kopchok G, Lippmann M, White R. Impact of an autotransfusion system during endoluminal repair of abdominal aortic aneurysms: does it decrease the use of allogeneic blood? Am Surg. 2005;71:786-90.
56. Nieder AM, Carmack AJ, Sved PD, et al: Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate. Urology. 2005;65:730-4. (Pubitemid 40523008)
57. Rebarber A, Lonser R, Jackson S, Copel JA, Sipes S. The safety of intraoperative autologous blood collection and autotransfusion during cesarean section. Am J Obstet Gynecol. 1998;179: 715-20. (Pubitemid 28447252)
58. Priuli G, Darate R, Perrin RX, Lankoande J, Drouet N. Multicentre experience with a simple blood salvage technique in patients with ruptured ectopic pregnancy in sub-Sahelian West Africa. Vox Sanguinis. 2009;97:317-23.
59. Bowley DM, Barker P, Boffard KD. Intraoperative blood salvage in penetrating abdominal trauma: a randomised, controlled trial. World J Surg. 2006;30:1074-80. (Pubitemid 43824421)
60. Muñoz M, Slappendel R, Thomas D. Laboratory characteristics and clinical utility of post-operative cell salvage: washed or unwashed blood transfusion? Blood Transfus. 2011;9:248-61.
61. Waters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion 2012 doi: 10.1111/j.1537-2995. 2011.03555.x. [Epub ahead of print].
62. Johansson PI. Coagulation monitoring of the bleeding traumatized patient. Curr Opin Anesthesiol. 2012,25:235-41.
63. Kozek-Langeneckerr SA. Perioperative coagulation monitoring. Best Pract Res Clin Anaesth. 2010;24:27-40.
64. Frith D, Davenport R, Brohi K. Acute Traumatic coagulopathy. Curr Opin Anesthesiol. 2012;25:229-34.
65. Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottemberg E, Thielmann M, et al. First-line with coagulation factor concentrates combined with poin-of-care coagulation testing is associated with decreased allogeneic Blood transfusion in cardiovascular surgery. Anesthesiology. 2011;115:1179-91.
66. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostatic target for the management of acquired bleeding. Anesth Analg. 2012;114:261-74.
67. Afshari A, Wikkelso A, Brok J, Moller AM, Wettersler J. TEG or ROTEM to monitor haemotherapy versus usual care in patients with massive transfusion. The Cochrane Library 2011;Issue 3.
68. Kalina U, Bickard H, Schulte S. Biochemical comparison of seven commercially available prothrombin concentrates. Int J Clin Pract. 2008;62:1614-22.
69. Bhagirath UC, O'Malley L, Crowther MA. Management of bleeding complications in the anticoagulated patient. Semin Hematol. 2011;48:285-94.
70. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal; a prospective multinational clinical trial; J Thromb Haemost. 2008;6:622-31. (Pubitemid 351404929)
71. Lankiewicz MW, Hays J; Friedman KD, Tinkoff G. Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4:967-70.
72. Lubetsky A, Hoffman R; Zimlichman R; Eldor A; Zvi J; Kosetnko V, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Tromb Res. 2004;113: 371-8. (Pubitemid 38844367)
73. Holbrrok A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence based management of anticoagulant therapy. ACCP guidelines. Chest. 2012;141:(2) (suppl):e152S-e184S.
74. Ferraris VA, Brown JR, Despotis GJ, et al. Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. International Consortium for Evidence Based Perfusion. Ann Thorac Surg. 2011;91:944-82.
75. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39:2993-6.
76. Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71:1084-489.
77. Aiyagari V, Testai FD. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care. 2009;15:87-92.
78. Kuwashiro T, Yasaka M, Itabashi R, Nakagaki H, Miyashita F, Naritomi H, et al. Enlargement of Acute Intracerebral Hematomas in Patients on Long-Term Warfarin Treatment. Cerebrovasc Dis. 2010;29:446-53.
79. Morgensterm LB, Hemphill JD, Anderson C, Becker K, Broderick JP, Conno lly ES, et al. Guideline for the management of spontaneous intracerebral hemorrhage, AHA/ASA guideline. Stroke. 2010;41:2108-29.
80. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011;117:6091-9.
81. Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465-70. (Pubitemid 44305727)
82. Siddiq F, Jalil A, McDaniel C, Brock DG, Pineda CC, Bell RD, et al. Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care. 2008;8:36-41. (Pubitemid 351378107)
83. Godier A, Samana CM. Plasma /platelets /red blood cell ratio in the management of the bleeding traumatized patient. Does it matter? Curr Opin Anaesthesiol. 2012;25:242-7.
84. Dirks J, Jorgensen H, Jensen CH, Osttowski SR, Johansson PI. Blood product ratio in acute traumatic coagulopathy effect in a Scandinavian level 1 trauma center. Scand J Trauma Resusc Emerg Med. 2010;18:65.
85. Joseph B, Amini A, Friese RS, Houdek M, Hays D, Kulvatunyou N, et al. Factor IX complex for the correction of Traumatic coagulopathy. J Trauma Acute Care Surg. 2012;72:828-34.
86. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin k reversal and treatment of severe bleeding. Critical Care. 2009;13:R191.
87. Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter D, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol. 2003;15:15-20. (Pubitemid 36135657)
88. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemosthasis in critically ill patients. Br J Haematol. 2004;125:69-73. (Pubitemid 38453280)
89. Leal-Noval SR, Arellano V, Maestre A, Muñoz M, Fernández V, Ferrándiz C, et al. Impact of national transfusion indicators on appropriate Blood usage in critically ill patients. Transfusion. 2011;51:1957-65.
90. Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke. 2011;42:191-5.
91. Yuan ZH, Jiang JK, Huang WD, Zhu JY, Wang JZ. A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosc. 2010;17:685-93.
92. Khorsand N, Veeger NJ, Muller M, Overdiek JW, Huisman W, van Herst RM, et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Tranfus Med. 2011;21:116-23.
93. Vigué D. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage -from theory to practice. Crit Care. 2009;R13:209.
94. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates, evaluation of safety and Thrombogenicity. Crit Care. 2011;15:201.
95. Rahe-Meyer N, Sorensen B. Fibrinogen concentrate for management of bleeding. J Thromb Haemost. 2011;9:1-5.
96. Ozier Y, Hunt BJ. Fibrinogen concentrate for management of bleeding: againts indiscriminate use. J Thromb Haemost. 2011;9:6-8.
97. Solomon C, Pichlmaier U, Schoechl H, Hagl C, Raymondos K, Scheinichen D, et al. Recovery of fibrinogen after administration of fibrinogen concéntrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth. 2010;104:555-62.
98. Fries D, Martini Dz. Role of fibrinogen in trauma -induced coagulopathy. Br J Anaesth. 2010;105:116-21.
99. Rossaint R, Bouillon B, Lerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care. 2010;14:R52.
100. Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ, et al. The ratio of fibrinogen to red blood cell transfused affects survival in casualties receiving massive transfusion at an army combat support hospital. J Trauma. 2008;64:S79-85.
101. Schöchl H, Nienaber U, Maegele M, Huchleitner G, Primavesi F, Steitz B, et al. Transfusion in trauma: thromboelastometry -guided coagulation factorconcentrate -based therapy versus standard fresh frozen plasma -based therapy. Crit Care. 2011;15:R83.
102. Mell MW, O'Neil AS, Callcut RA, Acher CW, Hoch JR, Tefera G, et al. Effect of early plasma transfusion on mortality in patients with ruptura abdominal aortic aneurism. Surgery. 2010;148:955-62.
103. Lancé MD, Ninivaggi M, Schols SE, Feijge MA, Oehrl SK, Kuiper GJ, et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang 2011; Dec 28.
104. Fenger-Eriksen C, Jensen TM, Kristensen TM, Jensen KM, Tonnesen E, Ingerslev J, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebocontrolled clinical trial. J Thromb Haemost. 2009;7:795-802.
105. Bell SF, Rayment R, Collins PW, Collins RE. The use of fibrinogen concéntrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anaesth. 2010;19:218-23.
106. Weiss G, Lison S, Glaser M, et al. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register. Blood Coagul Fibrinolysis. 2011;22:727-34.
107. Ogawa S, Szlam F, Chen EP, et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion. 2012;52:14-22.
108. Fernández-Hinojosa, Murillo-Cabezas F. Alternativas terapéuticas de la hemorragia masiva. Med Intensiva 2012. En prensa.
109. Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011;93:39-46.
110. Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011;93:1577-85.
111. Ipema HJ, Tanzi MG. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother. 2012;46:97-107.
112. Wong J, El Beheiry H, Rampersaud YR, Lewis S, Ahn H, De Silva Y, et al. Tranexamic Acid reduces perioperative blood loss in adult patients having spinal fusion surgery. Anesth Analg. 2008;107:1479-86.
113. Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine (Phila Pa 1976). 2008;33:2577-80.
114. Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology. 2005;102:727-32. (Pubitemid 40462851)
115. Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology. 2006;105:1034-46. (Pubitemid 44655516)
116. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a metaanalysis. CMAJ. 2009;180:183-93.
117. Adler Ma SC, Brindle W, Burton G, Gallacher S, Hong FC, Manelius I, et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2011;25:26-35.
118. Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth. 2009;56:202-12.
119. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-31. (Pubitemid 351749156)
120. McIlroy DR, Myles PS, Phillips LE, Smith JA. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. Br J Anaesth. 2009;102:168-78.
121. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2007;7:185-94. (Pubitemid 44952872)
122. Wu CC, Ho WM, Cheng SB, Yeh DC, Wen MC, Liu TJ, et al. Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a «blood transfusion»-free hepatectomy. Ann Surg. 2006;243:173-80.
123. Gungorduk K, Yildirim G, Asicio lu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011;28:233-40.
124. Crescenti A, Borghi G, Bignami E, Bertarelli G, Landoni G, Casiraghi GM, et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ. 2011;343:d5701.
125. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23-32.
126. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147:113-9.
127. Henry DA, O'Connell DL. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ. 1989;298:1142-6. (Pubitemid 19121348)
128. Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth. 2012;59:6-13.
129. Montes FR, Pardo DF, Carreño M, Arciniegas C, Dennis RJ, Umaña JP. Risk factors associated with postoperative seizures in patients undergoing cardiac surgery who received tranexamic acid: a casecontrol study. Ann Card Anaesth. 2012;15:6-12.
130. Carless PA, Henry DA, Moxey AJ, O'Connell D, McClelland B, Henderson KM, et al. Desmopressing for minimimising perioperative allogeneic blood transfusion. Cochrane database syst rev 2004;1, CD 001884.
131. Aguado MJ, Molina JM, Villegas R. Uso adecuado del factor VII activado recombinante en pacientes no hemofílicos. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Sevilla; 2010. AETSA 2007/04.
132. Zangrillo A, Mizzi A, Biondi-Zoccai G, Bignami E, Calabrò MG, Pappalardo F, et al. Recombinant activated factor VII in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2009;23:34-40.
133. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;7;120:21-7.
134. Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, et al. CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010;69:489-500.
135. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-37. (Pubitemid 351679599)
136. Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled study. Hepatology. 2008;47:1604-14. (Pubitemid 351702743)
137. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154:529-40.
138. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke. 2010;41:48-53.
139. Levy M, Levy J, Andersen H, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791-800.
140. Lidder PG, Sanders G, Whitehead E, Douie WJ, Mellor N, Lewis SJ, Hosie KB. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery -A prospective, randomised, controlled trial. Ann R Coll Surg Engl. 2007;89:418-21. (Pubitemid 46767051)
141. Okuyama M, Ikeda K, Shibata T, Tsukahara Y, Kitada M. Preoperative iron supplementation and intraoperative transfusion during colorectal cancer surgery. Surg Today. 2005;35:36-40. (Pubitemid 40941128)
142. Cuenca J, Garcia-Erce JA, Martinez F, Cardona R, Perez-Serrano L, Munoz M. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg. 2007;5:89-94. (Pubitemid 46590853)
143. Rogers BA, Cowie A, Alcock C, Rosson JW. Identification and treatment of anaemia in patients awaiting hip replacement. Ann R Coll Surg Engl. 2008;90:504-7.
144. Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty J Bone Joint Surg [Br]. 2005;87-B:213-17. (Pubitemid 40278023)
145. Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am. 2010;92-A:265-9.
146. Crosby L, Palarski VA, Cottington E, Cmolik B. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. Heart Lung. 1994; 23:493-9. (Pubitemid 24378723)
147. Pieracci FM, Henderson P, Macmillan Rodney JR, Holena DN, Genisca A, Benkert IIS, et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect. 2009;10:9-19.
148. Bisbe E, García-Erce JA, Díez-Lobo AI, Muñoz M. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107:477-8.
149. Díaz-Espallardo C, Laso-Morales MJ, Colilles-Calvet C, Mora-López L, Roig-Martínez I, Martínez-Marín MT. El abordaje multidisciplinar es útil para la optimización de la hemoglobina preoperatoria en cirugía neoplásica colorrectal. Cir Esp. 2011;89:392-9.
150. Edwards TJ, Noble EJ, Durran A, Mellor N, Hosie KB. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg. 2009;96:1122-8.
151. Cuenca J, Garcia-Erce JA, Munoz M, Izuel M, Martinez AA, Herrera A. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Transfusion. 2004; 44:1447-52.
152. Cuenca J, Garcia-Erce JA, Martinez AA, Solano VM, Molina J, Munoz M. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg. 2005;125: 342-7. (Pubitemid 40895356)
153. Serrano-Trenas JA, Font-Ugalde P, Muñoz-Cabello L, Castro-Chofles L, Rodríguez-Fernández PJ, Carpintero-Benítez P. Role of perioperative intravenous iron therapy in elderly hip fracture patients. A single center randomized controlled trial. Transfusion. 2001;51:97-104.
154. García-Erce JA, Cuenca J, Muñoz M, Izuel M, Martínez AA, Herrera A, et al. Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sang. 2005;88:235-43. (Pubitemid 40704896)
155. García-Erce JA, Cuenca J, Haman-Alcober S, Martínez AA, Herrera A, Muñoz M. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. Vox Sang. 2009;97:260-7.
156. Cuenca J, Garcia-Erce JA, Martinez F, Perez-Serrano L, Herrera A, Munoz M. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogenic blood after knee replacement surgery. Transfusion. 2006; 46:1112-9. (Pubitemid 44139484)
157. Madi-Jebara SN, Sleilaty GS, Achouh PE, Yasigi AG, Hadad FA, Hayek GM, Antakly MCJ, Jebara VA. Postoperative intravenous iron used alone or in combination with low-dose erythropietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth. 2004;18:59-63. (Pubitemid 38240762)
158. Muñoz M, Naveira E, Seara J, Cordero J. Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty. Br J Anaesth. 2012;108:532-4.
159. Berniére J, Dehullu JP, Gall O, Murat I. Intravenous iron therapy for correction of post-operative anemia following spinal surgery in children. Revue de chirurgie orthopédique. 1998;84:319-22. (Pubitemid 28313311)
160. Gredilla E, Gimeno M, Canser E, Martínez B, Pérez Ferrer A, Gilsanz F. Tratamiento de la anemia en el postparto y en el postoperatorio inmediato de cirugía ginecológica, con hierro intravenoso. Rev Esp Anestesiol Reanim. 2006;53:208-13.
161. Armand-Ugón R, Cheong T, Matapandewu G, Rojo-Sanchís A, Bisbe E, Muñoz M. Efficacy of intravenous iron for treating postpartum anemia in low-resource African countries: a pilot study in Malawi. J Womens Health (Larchmt). 2011;20:123-7.
162. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG. 2006;113:1248-52.
163. Westad S, Backe B, Salvesen KA, Nakling J, Økland I, Borthen I, et al. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand. 2008;87:916-23.
164. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267-78. (Pubitemid 47356650)
165. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199:435.e1-7.
166. Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503-9.
167. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009:1-8.
168. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182-92. (Pubitemid 351677967)
169. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846-53.
170. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105:199-204. (Pubitemid 46441460)
171. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116:522-5.
172. García-Erce JA, Fernández C, Lao J, Muñoz M. Meta-análisis de la eficacia y seguridad de hierro endovenoso en el tratamiento de la anemia, en pacientes oncológicos tratados con agentes estimulantes de la eritropoyesis. Hematologica (edición española). 2009;94 (extra 2):138.
173. Hedenus M, Birgegård G, Näsman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627-32. (Pubitemid 46444544)
174. Chertow GM, Mason PD, Vaaga-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-82. (Pubitemid 43159991)
175. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, et al. Serious Hazards of Transfusion: A Decade of Hemovigilance in the UK. Transfus Med Rev. 2006;20:272-82.
176. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623-32. (Pubitemid 38679688)
177. Harju E. Empty iron stores as a significant risk factor in abdominal surgery. J Parent Enteral Nutr. 1988;12:282-5.
178. Izuel Rami M, García Erce JA, Gómez-Barrera M, Cuenca Espiérrez J, Abad Sazatornil R, Rabanaque Hernández MJ. Relación entre la transfusión de sangre alogénica, la deficiencia de hierro y la infección nosocomial en pacientes con fractura de cadera. Med Clin (Barc). 2008;131:647-52.
179. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. Transfus Med. 1998;8:309-17. (Pubitemid 28552019)
180. Feagan BG, Wong CJ, Kirkley A, Johnston DWC, Smith FC, Whitsitt P, et al. Erythropoietin with iron supplementation to prevent allogenic blood transfusion in total hip joint arthroplasty. Ann Intern Med. 2000;133:845-54.
181. Weber EWG, Slappendel R, Hémon Y, Mähler S, Dálen T, Rouwet E, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol. 2005;22;249-57. (Pubitemid 40731986)
182. Karkouti K, McCluskey SA, Evans L, Mahomed N, Ghannam M, Davey R. Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery. Can J Anesth. 2005;52;4:363-8.
183. Alghamdi AA, Albanna MJ,Guru V, Brister SJ. Does the Use of Erythropoietin Reduce the Risk of Exposure to Allogeneic Blood Transfusion in Cardiac Surgery? A Systematic Review and Meta-Analysis. J Card Surg. 2006;21:320-6.
184. Ootaki Y, Yamaguchi M, Yoshimura N, Oka S, Yoshida M, Hasegawa T. The efficacy of preoperative administration of a single dose of recombinant human erythropoietin in pediatric cardiac surgery. Heart Surg Forum. 2007;10:E115-9.
185. Weltert L, D'Alessandro S, Nardella S, Girola F, Bellisario A, Maselli D, et al. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg. 2010;139:621-6; discussion 626-7.
186. Yoo YC, Shim KK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology. 2011;115:929-37.
187. Qvist N, Boesby S, Wolf Birgit, Hansen CP. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative periods: reduced nee for blood transfusions in patients undergoing colorectal surgery -Prospective doubleblind placebo-controlled study. World J Surg. 1999;23:30-5. (Pubitemid 28565556)
188. Kosmadakis N, Messaris E, Maris A, Katsaragakis S, Leandros E, Konstandoulakis MM, et al. Perioperative erythropioietin administration in patients with gastrointestinal tract cancer. Prospective randomized double blind study. Ann Surg. 2003;237:417-21. (Pubitemid 38176458)
189. Christodoulakis M, Tsiftsis DD. For the Hellenic Surgical Oncology Perioperative EPO Study Group. Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study. Ann Surg Oncol. 2005;12:718-25. (Pubitemid 41206918)
190. Zarychansky R, Turgeron AB, McIntyre L, Fergusson DA. Erythropoietin-receptor agonist in critical ill patients: A meta-analysis of randomised controlled trials. CMAJ. 2007;177:725-34. (Pubitemid 47523553)
191. Muñoz M, García-Erce JA, Leal-Noval SR. ¿La eritropoyetina humana recombinante es aún una alternativa válida para el tratamiento de la anemia del paciente crítico? Med Clin (Barc). 2009;132:749-55.
192. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965-76. (Pubitemid 47367076)
193. Talving P, Lustenberger T, Inaba K, Lam L, Mohseni S, Chan L, et al. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. Arch Surg. 2012;147:251-5.
194. Rosencher N, Poisson D, Albi A, Aperce M, Barré J, Samama M. Two injections of erythropoietin correct moderate anemia in most patients awaiting orthopedic surgery. Can J Anesth. 2005;52:160-5. (Pubitemid 40467973)
195. Gonzalez-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med. 2009; 19:35-42.
196. Feagan BG, Wong CJ, Kirkley A, Johnston DW, Smith FC, Whitsitt P, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000;133:845-54.
197. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G. An openlabel, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976). 2009;34:2479-85.
198. Dahl NV, Henry DH, Coyne DW. Thrombosis with erythropoietic stimulating agents: does iron-deficient erythropoiesis play a role? Semin Dial. 2008;21:210-1.
199. Basora M, Fita G, Matute P, Díaz-Ricart M. Safety concerns about perisurgical epoetin treatment: should we add antiplatelet drugs to perisurgical epoetin alfa treatment? J Cardiothorac Vasc Anesth. 2007;21:623-4. (Pubitemid 47126890)
200. Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G. Colloids versus crystalloids for fluid resucitation in critically ill patients (Cochrane Review). En: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons; 2004.
201. Pargger H, Studer W, Ruttimann U. Volume therapy in hypotensive trauma patients. Schweiz Med Wochenschr. 2000;130:1509-15.
202. Soreide E, Deakin CD. Pre-hospital fluid therapy in the critically injured patient -a clinical update. Injury. 2005;36:1001-10. (Pubitemid 41132787)
203. Nolan J. Fluid resuscitation for the trauma patient. Resuscitation. 2001;48:57-69. (Pubitemid 32121665)
204. Shafi S, Kauder DR. Fluid resuscitation and blood replacement in patients with polytrauma. Clin Orthop Relat Res. 2004;422:37-42. (Pubitemid 38685474)
205. Santry HP, Alam HB. Fluid resuscitation: past, present, and the future.Shock. 2010;33:229-41.
206. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg. 2008;107: 382-90.
207. Stainsby D, MacLennan S, Thomas D, Isaac J and Hamilton PJ. Guidelines on the management of massive blood loss. British Journal of Haematology. 2006;135:634-41. (Pubitemid 44674073)
208. Holcomb JB, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008;248:447-58.
209. Nakstad AR, Skaga NO, Pillgram-Larsen J, Gran B, Heier HE. Trends in transfusion of trauma victims-evaluation of changes in clinical practice. Scand J Trauma Resusc Emerg Med. 2011;11:19-23.
210. Rajasekhar A, Gowing R, Zarychanski R, Arnold DM, Lim W, Growther MA, et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Criti Care Med. 2011;39:1507-13.
211. Nascimento B, Callum J, Rubenfeld G, Neto JB, Lin Y, Rizoli S. Clinical review: Fresh frozen plasma in massive bleedings -more questions than answers. Crit Care. 2010;14:202.
212. Stansbury LG, Dutton RP, Stein DM, Bochicchio GV, Scalea TM, Hess Jr. Controversy in trauma resuscitation: do ratios of plasma to red blood cells matter? Transfus Med Rev. 2009;23:255-65.
213. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000567.
214. Perner A, Haase N, Guttormse AB, Tenhumen J, Klemenzson G, Aneman A, et al. Hydroxyethyl starch 130/0.4 versus ringer acetate in seve sepsis. New Eng J Med 2012;DOI:10.256/NEJMoa1204242.
215. Riess JG. Perfluorocarbon-based Oxygen Delivery. Artif Cell Blood Substit Biotechnol. 2006;34:567-80. (Pubitemid 44720156)
216. Maevsky E, Ivanitsky G, Bogdanova L, et al. Clinical results of Perftoran application: present and future. Artif Cell Blood Substit Biotechnol. 2005;33:37-46. (Pubitemid 40315177)
217. Cohn CS, Cushing MM. Oxygen therapeutics: Perfluorocarbons and blood substitute safety. Crit Care Clin. 2009;25:399-414.
218. Verdín-Vasquez RC, Zepeda-Pérez C, Ferra-Ferrer R, et al. Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: clinical trial. Artif Cell Blood Substit Biotechnol. 2006;34:433-54. (Pubitemid 44024996)
219. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: Efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma. 2008;64:1484-97.
220. Cothern C, Moore EE, Offner PJ, et al. Blood substitute and erythropoietin therapy in severely anemic Jehovah's Witness. N Engl J Med. 2002;346:1097-8. (Pubitemid 34984633)
221. Moore EE, Moore FA, Fabian TC, et al. human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: The USA multicenter trial. J Am Coll Surg. 2009;208:1-13.
222. Olofsson C, Nygards EB, Ponzer S, et al. A randomized, singleblind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med. 2008;18:28-39. (Pubitemid 351239315)
223. Silverman TA, Weiskopf RB. Hemoglobin-based oxygen carriers: current status and future directions. Anesthesiology. 2009;111:946-63.